The Oncology Care Model (OCM) over the last couple of years has helped us to look at things that we didn’t really think of from an oncology perspective, explained Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd.
The Oncology Care Model (OCM) over the last couple of years has helped us to look at things that we didn’t really think of from an oncology perspective, explained Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd.
Transcript
A few years into the Oncology Care Model and other value-based models, have community oncologists gotten better at practicing the business of oncology?
It’s a difficult question in the sense that community oncology, they weren’t businessmen. Doctors don’t go to medical school to get a business degree and unfortunately, in our healthcare environment, if you’re going to be an independent practice, you have to understand the business of medicine that you’re in, and I think that OCM over the last couple of years has helped us too look at things that we didn’t really think of from an oncology perspective.
You’re always looking at the patient first, you’re always looking at that patient outcome, but now we have to look at the total cost of care, we have to look at that patient engagement piece—not just saying that we did it, but documenting it and having those documented interactions, which is something for more the payers than really the patient.
So, I do think that oncologists have become better business people because they’ve had to in order to survive in this environment and be able to take care of their patients in a better way.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More